Aradigm (ARDMQ) 8-K Aradigm Announces First Quarter 2011 Financial Results

Exhibit 99.1

Aradigm Announces First Quarter 2011 Financial Results

Hayward, CA — May 12, 2011 — Aradigm Corporation (OTC BB: ARDM.OB)(the “Company”) today announced financial results for the first quarter and three months ended March 31, 2011.

Total revenue was $0.2 million for the first quarter of 2011, compared with $4.0 million in revenue for the first quarter of 2010. Revenue for the first quarter of 2010 reflects the receipt of the milestone payment due from Zogenix, Inc. upon the first U.S. sale of SUMAVEL* DosePro* needle-free delivery system for treatment of acute migraine and cluster headaches. Revenue for the first quarter of 2011 reflects the quarterly royalty payment from Zogenix for SUMAVEL product sales.

Total operating expenses for the first quarter of 2011 were $2.6 million, compared with total operating expenses of $4.1 million for the first quarter of 2010. The decrease in operating expenses was primarily due to expense reduction efforts and lower expenses from the Company’s inhaled liposomal ciprofloxacin clinical trials. The Company’s net loss for the first quarter of 2011 was $2.4 million, or $0.01 per share, compared with a net loss of $0.2 million, or $0.00 per share, for the same period in 2010.

As of March 31, 2011, cash, cash equivalents and short-term investments totaled $3.1 million.

Recent Highlights

• Dr. Paul Bruinenberg, the Company’s Senior Medical Director, will be presenting a poster at the American Thoracic Society’s 2011 ATS International Conference in Denver, Colorado on May 17, 2011. The poster title is “Inhaled Liposomal Ciprofloxacin Significantly Reduces SputumPseudomonas Aeruginosa(PA) Density and Increases Time to First Exacerbation in a 168 day Placebo Controlled Study in Non-Cystic Fibrosis Bronchiectasis” and will present results from the Company’s ORBIT-2 clinical trial.

• The Company will be presenting a poster at the 34^th European Cystic Fibrosis Conference in Hamburg, Germany. The poster title is “Safety, Tolerability and Pharmacokinetics of Novel Liposomal Ciprofloxacin Formulations for Inhalation in Healthy Volunteers and Non-Cystic Fibrosis Bronchiectasis Patients” and will be available for viewing from June 8-June 11, 2011.

• The Company received Notices of Allowance from the U.S. Patent and Trademark Office for the Company’s trademark applications for Lipoquin™ and Pulmaquin™ to be used as marks for ARD-3100 and ARD-3150, respectively.

“We continue to make focused clinical and regulatory progress with our inhaled liposomal ciprofloxacin treatments ARD-3100 and ARD-3150, now known as Lipoquin™ and Pulmaquin™, and are projecting to report the results from the ORBIT-1 Phase 2b study in non-cystic fibrosis bronchiectasis later in the second quarter of 2011. We are also actively engaged in discussions with potential partners to move the inhaled liposomal ciprofloxacin program forward into Phase 3,” said Igor Gonda, CEO and President of Aradigm.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhaled bioterrorism infections and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the timing and results of clinical trials and the payment of royalties, as well as the other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2010 filed with the SEC on March 25, 2011, and the Company’s Quarterly Reports on Form 10-Q.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

* Other names and brands may be claimed as the property of others.

SOURCE: Aradigm Corporation

Contact: Nancy Pecota, Chief Financial Officer, 510-265-8800

ARADIGM CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

	Three months ended
	March 31,
	2011			2010
Revenues	$	182		$	4,000
Operating expenses:
Research and development		1,480			2,837
General and administrative		1,135			1,253
Restructuring and asset impairment		10			13
Total operating expenses		2,625			4,103
Loss from operations		(2,443	)		(103	)
Interest income		2			10
Interest expense		(7	)		(109	)
Other income (expense), net		1			(2	)
Net loss	$	(2,447	)	$	(204	)
Basic and diluted net loss per common share	$	(0.01	)	$	(0.00	)
Shares used in computing basic and diluted net loss per common share		170,135			99,872

ARADIGM CORPORATION
CONDENSED BALANCE SHEETS
(In thousands)

	March 31,		December 31,
	2011		2010
	(Unaudited)		*
ASSETS
Current assets:
Cash and cash equivalents	$	2,591	$	5,295
Short-term investments		501		251
Receivables		75		180
Prepaid and other current assets		181		180
Total current assets		3,348		5,906
Property and equipment, net		1,431		1,553
Notes receivable		55		54
Other assets		113		115
Total assets	$	4,947	$	7,628
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		190		257
Accrued clinical and cost of other studies		514		993
Accrued compensation		318		327
Facility lease exit obligation		104		99
Other accrued liabilities		585		450
Total current liabilities		1,711		2,126
Deferred rent		110		99
Facility lease exit obligation, non-current		703		729
Other non-current liabilities		75		75
Shareholders’ equity		2,348		4,599
Total liabilities and shareholders’ equity	$	4,947	$	7,628

* The balance sheet at December 31, 2010 has been derived from the audited financial statements at that date.

# # #